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ABSTRACT: Opioids are widely used analgesic medications with a high
potential for tolerance and dependence and represent a frequent cause of death
due to overdose. Opioids mediate their actions via a family of opioid G protein
coupled receptors. Elucidating the biochemical mechanism(s) responsible for
both the therapeutic and deleterious side effects of opioids could provide a
biochemical roadmap for selectively targeting therapeutic signaling pathways.
Here we provide a perspective on emerging findings, which illuminate these
signaling pathways via unbiased and quantitative phosphoproteomic analysis.
What emerged from these studies is the discovery that certain deleterious actions
mediated by the κ opioid receptors appear due to specific activation of mTOR
pathways. The findings imply that designing drugs, which bypass mTOR signaling,
could yield safer and more effective analgesics.
Opioid drugs like morphine and oxycodone are powerfulpainkillers that produce analgesia by activation of opioid
G-protein coupled receptors (GPCRs). Although opioids are
quite useful for alleviating pain, they can also elicit an array of
harmful side effects, such as aversion, hallucinations, addiction,
and death by respiratory depression. Thus, a new class of
nonopioid analgesics could go a long way toward alleviating
the prevailing opioid crisis. Alternatively, could we develop a
biased or functionally selective opioid that preferentially
produces desired effects and avoids undesired effects?1,2
Currently, there are many comprehensive cell-based assay
platforms (proximity, distribution, or signaling assay) available
to study biased agonism in vitro.3 However, the in vitro
pharmacology is frequently inconsistent with the in vivo
behavioral activities due to the complexity of signaling
networks in vivo. How to directly measure drug actions and
GPCR activities in real-time in vivo remains an underutilized
approach.
In a breakthrough study, Liu et al.4 applied an optimized
mass spectrometric approach to quantify phosphorylation
events in an unbiased way in the brain after drug
administration. Protein phosphorylation is considered to be
one of the most abundant as well as one of the most important
post-translation modifications for signaling networks. The κ
opioid receptor (KOR) was used as a model system along with
five KOR ligands (U-50,488H, 6′GNTI, RB64, HS665, and
HS666), which display differential in vitro and in vivo
pharmacology. In particular, two of the drugs, 6′GNTI and
HS666, do not induce the classical KOR-mediated aversion
that has been observed for U-50,488H, RB64, and HS665.
After administration of these five KOR agonists, Liu et al.
analyzed the phosphoproteomic architecture from five brain
regions (striatum, cortex, hippocampus, medulla oblongata,
and cerebellum), each having different levels of KOR
expression. The authors identified more than 50 000
phosphorylation sites after stimulation, and in combination
with the use of dynorphin- and KOR-knockout mice, they
identified the phosphorylation sites uniquely related to KOR
activation. The authors determined that the dynamic changes
in KOR phosphorylation displayed spatio-temporal control.
Further analysis of KOR-mediated phosphorylation identified
those patterns relevant to specific neuronal circuits, in
particular, dopamine-, glutamate-, and γ-aminobutyric acid
(GABA)-ergic signaling, thereby providing a connection
between KOR activation and signaling in these neurons.
They also explored the phosphorylation patterns between
pharmacologically different ligands. U-50,488H and 6′GNTI,
for instance, only shared 30−50% of the specifically identified
sites. Here we list some of the more interesting detailed
changes found after KOR activation by U50,4088H:
1) Phosphorylation of the extracellular signal-regulated
kinase ERK1 (Thr203 and Tyr205), the cannabinoid
receptor 1 (CB1, Ser317), the GABA-B receptor (Ser762),
the G protein γ subunit 12 (Ser7), and the NMDA
receptor 2a (Ser1459)
2) Dephosphorylation of dopamine- and cyclic adenosine
monophosphate-regulated neuronal phosphoprotein
(DARPP-32, pSer97) and the kinase Src (pSer17).
This observation of many dephosphorylation events implies
that both phosphatases and kinases are involved in the synaptic
signaling transduction pathways utilized by opioids.
Interestingly, some of these phosphorylation/dephosphor-
ylation events were brain-region specific. Dephosphorylation of
DARPP-32 exclusively occurred in the striatum and was
specific to Ser97, while phosphorylation of ERK1 was only
observed in the hippocampus. All of these could be
physiologically important because they play essential roles in
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regulating synaptic plasticity. Importantly, 6′GNTI and
HS666, which do not produce aversion in vivo, did not
regulate these sites, which implies that these phosphorylation
events are linked to this serious side effect of KOR activation.
The authors next focused on revealing the detailed pathways
that may be responsible for aversive behavior in vivo. Through
extensive bioinformatic analysis of signaling pathways regu-
lated only by U-50,488H, HS665, and RB64, the mechanistic
target of the rapamycin (mTOR) signaling pathway appeared
to be the most important. To determine whether the mTOR
pathway is related to the aversive actions of these drugs, the
mTOR-specific inhibitor temsirolimuc was applied followed by
U-50,488H, a KOR agonist that produces profound aversion.
As predicted, pretreatment with an mTOR inhibitor abolished
a measure of aversion (conditioned place aversion) in mice. In
addition, the mTOR inhibitor had no effects on U-50,488H-
mediated anticonculsive and antinociceptive effects, suggesting
that mTOR pathways are involved in the side effects but not
therapeutic actions of KOR opioids. These results imply that
the desired (antinociception) and undesired (aversion) effects
can be pharmacologically separated, at least for KOR opioids.
However, whether the aversion effect, or particularly the
mTOR pathway, is mediated by classical arrestin activation still
requires further research. A parallel study on nalfurafine (a
nonaversive drug at KOR)-mediated phosphoproteomic events
indicated that it does not activate the mTOR pathway either.5
Interestingly, nalfurafine was shown as a balanced KOR
agonist, which equally activates both the G protein and the
arrestin pathway in vitro,5 but whether it could activate the
arrestin pathway in vivo is unknown.
This work provides an exemplar of how unbiased
phosphoproteomics can reveal signaling pathways involved in
both the therapeutic and deleterious actions of KOR opioids.
The results also support the potential for combination therapy
(opioid plus mTOR inhibitor) as a promising approach for
pain therapeutics, although current mTOR inhibitors elicit
immunosuppressive side effects (Figure 1). This high-
throughput phosphoproteomic approach could be extended
to study downstream events of other GPCR members and
other families of proteins and thereby illuminate many of the
signaling events relevant to drug actions in the brain.
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Figure 1. Model of KOR agonist-mediated downstream signaling.
